Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

637135

registered interest
date	15/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	WiFi: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the risks posed by WiFi and related electromagnetic fields to children.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	52981
answer	answer is ministerial correction date of answer 22/11/2016 answer text <p>Government policy is that exposures to electromagnetic fields from Wi-Fi and other radio equipment should comply with the guidelines on limiting exposures from the International Commission on Non-ionizing Radiation Protection (ICNIRP).</p><p> </p><p>The former Health Protection Agency published a comprehensive review of the evidence prepared by its independent Advisory Group on Non-ionising Radiation in 2012. The Group’s overall conclusion was that although a substantial amount of research has been conducted in this area, there is no convincing evidence that electromagnetic field exposures below guideline levels cause health effects in either adults or children.</p><p> </p><p>Exposures from Wi-Fi equipment are well within the ICNIRP levels. Public Health England (PHE) advice is that there is no consistent evidence to date that exposures adversely affect the health of the general population. PHE has committed to keeping emerging evidence under review and preparing another comprehensive review when sufficient new evidence has accumulated.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 22/11/2016 14:36:56 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1486 label Biography information for Mr David Anderson

631859

registered interest
date	08/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Brain: Tumours
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Brain Tumour Research report on National Research Funding, published in October 2016, if he will make an assessment of the reasons for the 40 per cent increase in brain tumour diagnosis in the North East between 2011 and 2014.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	52243
answer	answer is ministerial correction date of answer 17/11/2016 answer text <p>These are matters for the local National Health Service.</p><p> </p><p>Public Health England advises that the National Cancer Registration and Analysis Service (NCRAS) collects data on all primary cancers diagnosed in England. The report from Brain Tumour Research shows that there were 241 brain cancers diagnosed in the North East in 2014, and NCRAS data shows that there were 210 diagnoses in 2011.</p><p> </p><p>NCRAS recommends that changes in cancer incidence are only compared using an age-standardised rate to ensure differences in the underlying population and changing age structure of an area are taken into account. The age-standardised rate of brain cancer incidence in the North East in 2014 was 9.5 per 100,000, and in 2011 was 8.4 per 100,000. As the number of new diagnoses is relatively small, it is not possible to say that any differences over time, or between the North East and the England average, are outside of that expected by random variation.</p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 52242 question first answered 17/11/2016 11:51:29 answering member 4080 label Biography information for David Mowat
tabling member	1486 label Biography information for Mr David Anderson

631860

registered interest
date	08/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Brain: Tumours
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Brain Tumour Research report on National Research Funding, published in October 2016, if he will launch a public enquiry into reasons for the 40 per cent increase in brain tumour diagnosis in the North East between 2011 and 2014.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	52242
answer	answer is ministerial correction date of answer 17/11/2016 answer text <p>These are matters for the local National Health Service.</p><p> </p><p>Public Health England advises that the National Cancer Registration and Analysis Service (NCRAS) collects data on all primary cancers diagnosed in England. The report from Brain Tumour Research shows that there were 241 brain cancers diagnosed in the North East in 2014, and NCRAS data shows that there were 210 diagnoses in 2011.</p><p> </p><p>NCRAS recommends that changes in cancer incidence are only compared using an age-standardised rate to ensure differences in the underlying population and changing age structure of an area are taken into account. The age-standardised rate of brain cancer incidence in the North East in 2014 was 9.5 per 100,000, and in 2011 was 8.4 per 100,000. As the number of new diagnoses is relatively small, it is not possible to say that any differences over time, or between the North East and the England average, are outside of that expected by random variation.</p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 52243 question first answered 17/11/2016 11:51:29 answering member 4080 label Biography information for David Mowat
tabling member	1486 label Biography information for Mr David Anderson

595800

registered interest
date	07/10/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the potential effect of the expansion of the Doctaly scheme on patients' access to GP services.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	46807
answer	answer is ministerial correction date of answer 17/10/2016 answer text <p>The Department has made no assessment of the potential effect of the expansion of the Doctaly scheme on patients’ access to general practice (GP) services.</p><p>The General Practice Forward View, published in April 2016, announced that an extra £2.4 billion a year will be invested in GP services by 2020/21. As part of overall investment in general practice, NHS England will provide over £500 million of recurrent funding by 2020/21, on top of current primary medical care allocations, to enable clinical commissioning groups to commission and fund extra capacity across England. This is to ensure that by 2020, everyone has access to GP services, including sufficient routine appointments at evenings and weekends to meet locally determined demand, alongside effective access to out of hours and urgent care services.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 17/10/2016 16:37:34 answering member 4080 label Biography information for David Mowat
tabling member	1486 label Biography information for Mr David Anderson

539585

registered interest
date	18/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health, House of Lords, 9 July 2015, Official Report, column 286, what his policy is on part funding of the NHS through insurance and co-payments.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	43034
answer	answer is ministerial correction date of answer 21/07/2016 answer text <p>There is no plan to change the way that the National Health Service is funded nor any consideration of changes. The Government remains committed to the principles of the NHS, enshrined in the NHS Constitution, that access to NHS services is based on clinical need, not the ability to pay.</p><p> </p><p>The Government is also committed to working with the NHS in implementing its own plan for the future of the NHS – the Five Year Forward View – backed up by the commitment made in the Spending Review to provide an additional £10 billion in real terms by 2020-21 compared to 2014-15. This fully funds the plan.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 43154 question first answered 21/07/2016 14:39:16 answering member 1542 label Biography information for Philip Dunne
tabling member	1486 label Biography information for Mr David Anderson

522580

registered interest
date	03/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mobile Phones: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the advice on mobile telephone safety on the NHS Choices webpages, what the evidence base is for the recommendation that children should only use mobile telephones for essential purposes and keep all calls short.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	39204
answer	answer is ministerial correction date of answer 13/06/2016 answer text <p>Public Health England (PHE) keeps the scientific evidence regarding the effects of exposure to electromagnetic fields from mobile phones on public health under review, and advises on the measures that should be taken to protect the public.</p><p> </p><p>Precautionary advice to discourage the non-essential use of mobile phones by children dates from the year 2000 and was motivated by concerns that, if there are unrecognised adverse health effects from the use of mobile phones, children may be more vulnerable. The advice was accepted by government and has been continued by Public Health England, including after its 2012 comprehensive review of research evidence, which found no convincing evidence that exposures to radiofrequency electromagnetic fields below the international guideline levels cause health effects in either adults or children. The precautionary advice is based on the potential for health effects, rather than proven identifiable evidence of harm.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/06/2016 16:49:38 answering member 3918 label Biography information for Jane Ellison
tabling member	1486 label Biography information for Mr David Anderson

522581

registered interest
date	03/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Mobile Phones
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will discuss with his US counterpart the potential implications for his policies of work undertaken by the US National Toxicology Program on links between mobile telephone use and levels of cancer risk; and if he will make a statement.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	39203
answer	answer is ministerial correction date of answer 13/06/2016 answer text <p>The Government looks to Public Health England (PHE) to review the scientific evidence regarding the effects of exposure to electromagnetic fields from mobile phones on public health, and to advise on the measures that should be taken to protect the public. Among the available evidence are the recently-released partial findings from a study carried out by the United States National Toxicology Programme, which involved rats exposed at levels substantially above those to which the public are exposed when using mobile phones. PHE has welcomed the first results of the study but consider the findings far from definitive with regard to any relationship between the use of mobile phones and cancer in humans.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/06/2016 16:40:24 answering member 3918 label Biography information for Jane Ellison
tabling member	1486 label Biography information for Mr David Anderson

522611

registered interest
date	03/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 25 May 2016 to Question 37646, what preparatory work NHS England is undertaking on Translarna; and whether a date has been set for a commercial meeting between NHS England and PTC Therapeutics after that preparatory work.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	39182
answer	answer is ministerial correction date of answer 10/06/2016 answer text <p>Further to the answer given in Question 37646, NHS England has been undertaking the detailed preparatory work required to meet the National Institute of Health and Care Excellence’s request that NHS England and the supplier, PTC Therapeutics, work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) by 7 July 2016.</p><p> </p><p>NHS England will be meeting with the supplier when it has concluded this preparatory work. There have not been any commercial meetings with PTC Therapeutics in the period since 15th April 2016 - however, NHS England is in regular contact with the supplier and will be agreeing mutually convenient times to meet.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/06/2016 10:55:25 answering member 4020 label Biography information for George Freeman
tabling member	1486 label Biography information for Mr David Anderson

519716

registered interest
date	19/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that NHS England implements the NICE recommendation for NHS funding for Translarna as a treatment for Duchenne muscular dystrophy.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	37645
answer	answer is ministerial correction date of answer 25/05/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The expected publication date for NICE’s final guidance is July 2016.</p><p>National Health Service commissioners are legally required to fund drugs and treatments recommended in NICE highly specialised technology guidance within three months of its final guidance being issued.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/05/2016 14:10:33 answering member 4020 label Biography information for George Freeman
tabling member	1486 label Biography information for Mr David Anderson

519718

registered interest
date	19/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many meetings NHS England has had with PTC Therapeutics to discuss an agreement on price for Translarna to treat Duchenne muscular dystrophy since 15 April 2016.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	37646
answer	answer is ministerial correction date of answer 25/05/2016 answer text <p>NHS England has advised that on 4 May 2016 the National Institute for Health and Care Excellence (NICE) asked NHS England and PTC Therapeutics to continue to work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) for the treatment of children aged five and over with Duchenne muscular dystrophy caused by a nonsense mutation.</p><p> </p><p>NHS England and the company have been asked to reach agreement on the cost of the drug to the National Health Service by 7 July.</p><p> </p><p>NHS England has advised there have not been any commercial meetings with PTC Therapeutics in the period since 15 April 2016, however, it is in regular contact with the company.</p><p> </p><p>NHS England will be meeting with PTC Therapeutics when it has concluded the detailed preparatory work required to effectively respond to NICE's request within the set timescale.<em> </em></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/05/2016 14:08:26 answering member 4020 label Biography information for George Freeman
tabling member	1486 label Biography information for Mr David Anderson